strong trikafta launch continu drive nt rev reit buy rais pt
trikafta traction remain infanc look ahead cf
believ strong uptak trikafta expect
emphas need assess addit metric truli judg
trikafta launch exampl believ averag patient durat
therapi emerg side effect toler issu continu
worth watch patient remain treatment believ
point investor survey physician could shed light trikafta
traction inform kol feedback earli trikafta adopt
highlight metric durabl respons discontinu
rate assess improv key mean
trikafta progress remain infanc look forward overal
treatment cf specif point beyond trikafta
launch patient age older addit mileston
horizon includ tripl combin approv eu patient
age older snda submiss tripl combin therapi
patient age year old potenti address earlier stage
diseas develop approv symkevi eu
patient age year old overal support earli
commerci traction indic trikafta pipelin progress
rais price target maintain buy
among broad pipelin believ aatd offer differenti
growth potenti note chronic weekli augment
therapi alon replac consid cure
address progress liver manifest antitrypsin
correct approach prevent protein misfold aatd vertex
emphas function serum level relev
along mention evalu liver biopsi phase analysi
consid possibl regulatori path believ remain unclear
compani plan incorpor reduct rate declin
kol convers character potenti
poor surrog marker emphysema chang emphysema
subtl furthermor believ ct densitometri
desmosine/ isodesmosin assess could offer broader insight
diseas statu improv specif believ
target prevent z-protein misfold liver
otherwis aggreg ultim pro-inflammatori lung
could conceiv serv possibl aatd cure note
kol discuss promis prospect affect patient
drug affect lung liver diseas vertex assert
small molecul corrector protein misfold could inde address
liver lung diseas aatd manifest first proof-
of-concept data expect note broaden
aatd corrector approach phase trial
compani second small molecul corrector aatd remain
on-going healthi volunt patient
definit distribut analyst rate analyst certif disclosur pleas refer page report
number vertex report total revenu research develop cost
fourth quarter full year respect sell gener administr expens
quarter full year respect compani report net incom
quarter full year decemb compani
report cash equival vertex guid total revenu view conserv
current project total revenu driven project qoq growth symdeko sale qoq growth
trikafta sale
valuat risk price target base equal weight composit
multipl tax dilut ep discount back npv
discount rate termin growth rate risk invest thesi target price includ failur
kalydeco orkambi tezacaftor combin clinic studi failur kalydeco
orkambi symdeko achiev peak sale revenu product competit
mm except per share valu
total orkambi revenu
incivo royalti janssen
hiv proteas inhibitor royalti gsk
revenu
revenu
revenu
revenu
revenu
chang fair valu deriv instrument
provis incom tax
loss attribut non-controlling interest
dcf analysi flow valu ms
chang work capit
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc vrtx-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl januari
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein matthew caufield alicia yin ph certifi view express report accur
reflect person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur vertex
pharmaceut inc includ without limit option right warrant futur long short posit
decemb neither firm affili benefici class common equiti secur
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within
twelv month seek compens compani mention report invest bank servic
within three month follow public research report
firm make market date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
